SPARC announces consolidation of R&D laboratories and facilities
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
Diversifying its portfolio to include late-phase antiviral agent
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Subscribe To Our Newsletter & Stay Updated